Johnson & Johnson announced it will reduce its workforce and restructure.
More than 4,000 employees - approximately 4% of the company's human resources - were scheduled to be let go during the fourth quarter of 1998. Johnson & Johnson had a total work force of 94,000 before the announcement.
The workforce reductions will not take place in its pharmaceutical sales division, the company clarified. Currently, the company employs nearly 3,000 pharmaceutical sales reps.
According to reports in the Wall Street Journal, 5,800 positions will be eliminated. The majority of the layoffs will take place in its manufacturing facilities. The company also announced that it will close 36 factories.
Altogether, the decision will cost Johnson & Johnson $800 million. The move, the company said, is part of a long-term effort to improve production efficiency and centralize manufacturing functions.
Over time, the restucturing could save the company $250 to $300 million per year. Those savings could be applied to the creation of 1,700 new positions, most likely in the sales and marketing departments.
The restructuring, industry analysts predict, will have little effect on the company's pharmaceutical business. PR
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.